{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:00:31Z","timestamp":1784833231041,"version":"3.55.0"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00482","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T04:20:59Z","timestamp":1526012459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":124,"title":["Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?"],"prefix":"10.3389","volume":"9","author":[{"given":"Fernanda F.","family":"Peres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro C.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina H.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa C.","family":"Ab\u00edlio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I","volume":"62","author":"Adams","year":"1940","journal-title":"J. Am. Chem. Soc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.nbd.2004.04.001","article-title":"A cell-based screen for drugs to treat Huntington's disease","volume":"16","author":"Aiken","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2018.03.001","article-title":"Current perspective of mitochondrial biology in Parkinson's disease","author":"Ammal Kaidery","year":"2018","journal-title":"Neurochem. Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0B013E3181633497","article-title":"Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study","volume":"32","author":"Aragona","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1602\/neurorx.2.3.484","article-title":"Toxin-induced models of Parkinson's disease","volume":"2","author":"Bov\u00e9","year":"2005","journal-title":"NeuroRx"},{"key":"B8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrn2337","article-title":"The pathophysiological basis of dystonias","volume":"9","author":"Breakefield","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1476-5381.1971.tb07089.x","article-title":"Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine","volume":"42","author":"Breese","year":"1971","journal-title":"Br. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J. Neurochem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.bbrc.2017.09.001","article-title":"Cannabidiol, a novel inverse agonist for GPR12","volume":"493","author":"Brown","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neuroscience.2014.12.051","article-title":"Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria","volume":"289","author":"Campos","year":"2015","journal-title":"Neuroscience"},{"key":"B13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518765649","article-title":"Balance worsening associated with nabiximols in multiple sclerosis","author":"Castelli","year":"2018","journal-title":"Mult. Scler. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","article-title":"GPR55: a therapeutic target for Parkinson's disease?","volume":"125","author":"Celorrio","year":"2017","journal-title":"Neuropharmacology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/jcpt.12179","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series","volume":"39","author":"Chagas","year":"","journal-title":"J. Clin. Pharm. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"","journal-title":"J. Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3892\/mmr.2016.5513","article-title":"Protective effect of cannabidiol on hydrogen peroxide induced apoptosis, inflammation and oxidative stress in nucleus pulposus cells","volume":"14","author":"Chen","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s00213-014-3478-5","article-title":"Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe\/PS1E9 mice","volume":"231","author":"Cheng","year":"2014","journal-title":"Psychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0011-15.2015","article-title":"Role of GPR55 during axon growth and target innervation","author":"Cherif","year":"2015","journal-title":"eNeuro"},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s40429-017-0142-2","article-title":"Does cannabis composition matter? differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition","volume":"4","author":"Colizzi","year":"2017","journal-title":"Curr. Addict. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/00207458608985678","article-title":"Open label evaluation of cannabidiol in dystonic movement disorders","volume":"30","author":"Consroe","year":"1986","journal-title":"Int. J. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ncl.2017.08.015","article-title":"Advanced symptom management in multiple sclerosis","volume":"36","author":"Crabtree-Hartman","year":"2018","journal-title":"Neurol. Clin."},{"key":"B26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","article-title":"Huntington's disease: can mice lead the way to treatment?","volume":"69","author":"Crook","year":"2011","journal-title":"Neuron"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington's disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2018.01.014","article-title":"Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol","volume":"139","author":"da Silva","year":"2018","journal-title":"Brain Res. Bull."},{"key":"B29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"B30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: from current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","article-title":"Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action","volume":"94","author":"Dos-Santos-Pereira","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/acprof:oso\/9780199662685.003.0001","article-title":"Constituents of Cannabis sativa","volume-title":"Handbook of Cannabis","author":"ElSohly","year":"2014"},{"key":"B34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2215-0366(17)30075-5","article-title":"Can we make cannabis safer?","volume":"4","author":"Englund","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.neuropharm.2013.07.024","article-title":"Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors","volume":"75","author":"Espejo-Porras","year":"2013","journal-title":"Neuropharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression","volume":"151","author":"Esposito","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e28668","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS ONE"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00213-011-2449-3","article-title":"Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders","volume":"219","author":"Fagherazzi","year":"2012","journal-title":"Psychopharmacology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"247467","DOI":"10.4061\/2011\/247467","article-title":"Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease","volume":"2011","author":"Farooqui","year":"2011","journal-title":"Parkinsons. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ane.12202","article-title":"Spasticity in patients with multiple sclerosis\u2013clinical characteristics, treatment and quality of life","volume":"129","author":"Flachenecker","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson's disease","volume":"163","author":"Garcia","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2017.06.015","article-title":"Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation","volume":"17","author":"Giacoppo","year":"","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.fitote.2016.11.010","article-title":"Target regulation of PI3K\/Akt\/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis","volume":"116","author":"Giacoppo","year":"","journal-title":"Fitoterapia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pnpbp.2013.06.005","article-title":"Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice","volume":"46","author":"Gomes","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.schres.2015.01.015","article-title":"Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol","volume":"164","author":"Gomes","year":"2015","journal-title":"Schizophr. Res."},{"key":"B47","first-page":"37","article-title":"A comparative study on some chemical and biological characteristics of various samples of cannabis resin","volume":"14","author":"Grlic","year":"1976","journal-title":"Bull. Narc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","article-title":"Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants","volume":"95","author":"Hampson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/bph.12615","article-title":"Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation","volume":"171","author":"Hassan","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.brainres.2007.09.090","article-title":"Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism","volume":"1188","author":"Hayakawa","year":"2008","journal-title":"Brain Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e29648","DOI":"10.1371\/journal.pone.0029648","article-title":"Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis","volume":"6","author":"Hecker","year":"2011","journal-title":"PLoS ONE"},{"key":"B52","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bph.13368","article-title":"Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARgamma and 5-HT1A receptors","volume":"173","author":"Hind","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","article-title":"Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users","volume":"25","author":"Hindocha","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington's disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","article-title":"Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells","volume":"89","author":"Iuvone","year":"2004","journal-title":"J. Neurochem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1037\/pha0000081","article-title":"Acute and chronic effects of cannabidiol on Delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced disruption in stop signal task performance","volume":"24","author":"Jacobs","year":"2016","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","author":"Jankovic","year":"2005","journal-title":"Mov Disord"},{"key":"B59","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.neuint.2011.12.002","article-title":"Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells","volume":"61","author":"Juknat","year":"2012","journal-title":"Neurochem. Int."},{"key":"B60","doi-asserted-by":"publisher","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B61","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00441-004-0975-6","article-title":"Parkinson's disease: clinical aspects","volume":"318","author":"Klockgether","year":"2004","journal-title":"Cell Tissue Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1074\/jbc.M109.069294","article-title":"Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta\/STAT proinflammatory pathways in BV-2 microglial cells","volume":"285","author":"Kozela","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/syn.10054","article-title":"Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease","volume":"44","author":"Lastres-Becker","year":"2002","journal-title":"Synapse"},{"key":"B65","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbrc.2017.05.165","article-title":"GPR3 and GPR6, novel molecular targets for cannabidiol","volume":"490","author":"Laun","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1111\/bph.13724","article-title":"Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders","volume":"174","author":"Lee","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/pcn.12270","article-title":"Tardive dyskinesia (syndrome): current concept and modern approaches to its management","volume":"69","author":"Lerner","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","volume":"31","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease","volume":"263","author":"L\u00f3pez-Send\u00f3n Moreno","year":"2016","journal-title":"J. Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/jmg.30.12.982","article-title":"Gametic but not somatic instability of CAG repeat length in Huntington's disease","volume":"30","author":"MacDonald","year":"1993","journal-title":"J. Med. Genet."},{"key":"B73","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors","volume":"8","author":"Mart\u00ednez-Pinilla","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease","volume":"79","author":"Mart\u00edn-Moreno","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1517\/14656566.2016.1109630","article-title":"Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature","volume":"17","author":"Mason","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1038\/cddis.2012.71","article-title":"Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress","volume":"3","author":"Mecha","year":"2012","journal-title":"Cell Death Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"Hashish\u2014I: the structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron"},{"key":"B80","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.parkreldis.2008.04.012","article-title":"Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol","volume":"14","author":"Meredith","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"B81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0197-0186(01)00076-6","article-title":"Noradrenaline release-inhibiting receptors on PC12 cells devoid of alpha(2(-)) and CB(1) receptors: similarities to presynaptic imidazoline and edg receptors","volume":"40","author":"Molderings","year":"2002","journal-title":"Neurochem. Int."},{"key":"B82","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/03602532.2018.1428616","article-title":"Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12","volume":"50","author":"Morales","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/can.2017.0036","article-title":"An update on non-CB1, non-CB2 cannabinoid related g-protein-coupled receptors","volume":"2","author":"Morales","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/can.2017.0034","article-title":"Chronic adolescent delta(9)-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment","volume":"2","author":"Murphy","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14147","article-title":"Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice","author":"Myers","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11910-018-0814-x","article-title":"The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews","volume":"18","author":"Nielsen","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12035-013-8483-x","article-title":"The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes","volume":"49","author":"Niranjan","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.neuroscience.2016.09.021","article-title":"Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity","volume":"337","author":"Oeckl","year":"2016","journal-title":"Neuroscience"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2014.04.010","article-title":"G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease","volume":"257","author":"Oeckl","year":"2014","journal-title":"Exp. Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","article-title":"A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia","volume":"72","author":"Osborne","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejphar.2009.03.010","article-title":"Time-dependent vascular actions of cannabidiol in the rat aorta","volume":"612","author":"O'Sullivan","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1124\/jpet.108.147181","article-title":"Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative\/nitrosative stress, inflammation, and cell death","volume":"328","author":"Pan","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/jnnp-2015-312591","article-title":"Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity","volume":"87","author":"Patti","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B94","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphar.2016.00343","article-title":"Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats","volume":"7","author":"Peres","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/BF01922823","article-title":"A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol","volume":"29","author":"Perez-Reyes","year":"1973","journal-title":"Experientia"},{"key":"B98","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1054\/plef.2001.0341","article-title":"Cannabinoid receptors and their ligands","volume":"66","author":"Pertwee","year":"2002","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"B100","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.fitote.2016.05.008","article-title":"Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages","volume":"112","author":"Rajan","year":"2016","journal-title":"Fitoterapia"},{"key":"B101","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000357742","article-title":"THC:CBD spray and MS spasticity symptoms: data from latest studies","volume":"71","author":"Rekand","year":"2014","journal-title":"Eur. Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0014-2999(02)02477-9","article-title":"Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia","volume":"454","author":"Richter","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus","volume":"165","author":"Rock","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/sj.bjp.0705467","article-title":"Anandamide and vanilloid TRPV1 receptors","volume":"140","author":"Ross","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.tips.2008.12.004","article-title":"The enigmatic pharmacology of GPR55","volume":"30","author":"Ross","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","article-title":"A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol","volume":"66","author":"Russo","year":"2006","journal-title":"Med. Hypotheses"},{"key":"B108","first-page":"3127","article-title":"Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study","volume":"20","author":"Russo","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-170283","article-title":"Cannabinoids for treatment of dystonia in Huntington's disease","author":"Saft","year":"2018","journal-title":"J. Huntingtons Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1179\/1743132812Y.0000000073","article-title":"Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease","volume":"34","author":"S\u00e1nchez-L\u00f3pez","year":"2012","journal-title":"Neurol. Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0165-1781(86)90117-4","article-title":"Cannabidiol in dystonic movement disorders","volume":"18","author":"Sandyk","year":"1986","journal-title":"Psychiatry Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tiv.2015.11.004","article-title":"The neuroprotection of cannabidiol against MPP(+)-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease","volume":"30","author":"Santos","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"B116","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav. Brain Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","article-title":"Mitochondrial complex I deficiency in Parkinson's disease","volume":"54","author":"Schapira","year":"1990","journal-title":"J. Neurochem."},{"key":"B118","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12640-014-9457-0","article-title":"Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice","volume":"26","author":"Schiavon","year":"2014","journal-title":"Neurotox. Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson's disease in primary care: a case-control study","volume":"14","author":"Schrag","year":"2015","journal-title":"Lancet Neurol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbr.2016.04.042","article-title":"Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice","volume":"309","author":"Sonego","year":"2016","journal-title":"Behav. Brain Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.neuropharm.2017.07.024","article-title":"Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors","volume":"125","author":"Stern","year":"2017","journal-title":"Neuropharmacology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm."},{"key":"B123","doi-asserted-by":"publisher","first-page":"E684","DOI":"10.3390\/ijms18040684","article-title":"Effects of a sativex-like combination of phytocannabinoids on disease progression in R6\/2 mice, an experimental model of Huntington's disease","volume":"18","author":"Valdeolivas","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B124","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1590\/1516-4446-2012-0886","article-title":"Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain","volume":"35","author":"Valvassori","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"B126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4684-5925-8_7","article-title":"Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro","volume-title":"Drugs of Abuse, Immunity, and Immunodeficiency","author":"Watzl","year":"1991"},{"key":"B127","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/08916930500356674","article-title":"Cannabidiol lowers incidence of diabetes in non-obese diabetic mice","volume":"39","author":"Weiss","year":"2006","journal-title":"Autoimmunity"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bph.12199","article-title":"Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol","volume":"170","author":"Wright","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"754","DOI":"10.4088\/JCP.v68n0513","article-title":"Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia","volume":"68","author":"Zhang","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"B130","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","article-title":"Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action","volume":"30","author":"Zuardi","year":"2008","journal-title":"Rev. Bras. Psiquiatr."},{"key":"B131","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson's disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T04:21:03Z","timestamp":1526012463000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":131,"alternative-id":["10.3389\/fphar.2018.00482"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00482","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"article-number":"482"}}